NCT07237100 2025-11-19Mirdametinib in Patients With Advanced NF1-mutant MelanomaSutter HealthPhase 2 Recruiting10 enrolled
NCT03962543 2025-08-07ReNeuSpringWorks Therapeutics, Inc.Phase 2 Active not recruiting114 enrolled 25 charts 1 FDA
NCT05028166 2024-03-15Individual Patient Compassionate Use of MirdametinibSpringWorks Therapeutics, Inc.Available